Abaloparatide

POPULAR 2026 | RESEARCH LIBRARY

Abaloparatide

An evidence-based, plain-language information page on this PTH-related protein analogue, its osteoporosis evidence, safety, regulatory status and South African relevance.

Contents

What abaloparatide is

Important information and disclaimer

Approved and researched uses

Potential future uses

How it works

What evidence has found

Current regulatory and South African status

How it compares

Risks and uncertainties

Treatment and measurement safeguards

Common questions

Join for updates

Sources

Important information and disclaimer

This page is for general education. Abaloparatide is a prescription medicine in jurisdictions where it is authorised and must be selected, prescribed and monitored by an appropriately qualified healthcare professional. This page does not diagnose osteoporosis, recommend treatment, replace registered product information, or provide personal injection or dosing instructions.

A vial or powder labelled ‘abaloparatide’, ‘PTHrP analogue’, ‘Tymlos’, ‘Eladynos’ or ‘research grade’ is not thereby equivalent to an authorised medicine. Identity, exact sequence, peptide content, purity, sterility, formulation, stability, delivery-device accuracy and cold-chain history may be unknown. A brand name must not be used for unrelated bulk material.

Collapse, severe allergic symptoms, persistent faintness, chest symptoms, a sustained racing or irregular heartbeat, severe weakness, confusion or symptoms suggesting a marked calcium disturbance require urgent medical assessment.

What is abaloparatide?

Abaloparatide is a synthetic 34-amino-acid analogue of human parathyroid hormone-related protein, or PTHrP(1-34). It activates the type 1 parathyroid hormone receptor (PTH1R). When delivered intermittently as a regulated medicine, it stimulates bone formation and can reduce fracture risk in appropriately selected people with osteoporosis.

Identity distinctions that prevent confusion

What is abaloparatide approved or researched for?

Authorised indications differ by jurisdiction. The current United States label covers postmenopausal women with osteoporosis at high risk for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. It also covers men with osteoporosis at high risk for fracture, or men who have failed or are intolerant to other available therapy. The European Union authorisation is for postmenopausal women with osteoporosis at increased fracture risk.

Reducing vertebral and non-vertebral fracture risk in postmenopausal osteoporosis

Increasing bone mineral density in women at high fracture risk

Increasing bone mineral density in men with osteoporosis at high fracture risk under the US label

Use as part of a longer osteoporosis strategy, commonly followed by an antiresorptive medicine to preserve bone gains

Authorisation does not make abaloparatide a general anti-ageing, bodybuilding, sports-recovery or ordinary fracture-healing treatment. A patient’s fracture history, bone density, secondary causes, kidney function, calcium status, previous medicines and overall risk affect whether an anabolic medicine is appropriate.

Other potential uses—only if future research confirms them

Researchers continue to study the best sequence and timing of anabolic and antiresorptive therapy, treatment in additional osteoporosis subgroups, and whether anabolic PTH1R signalling can improve selected fracture-healing or surgical bone outcomes. These questions are not the same as routine authorised use.

A biological rationale or a small study does not establish benefit for healthy ageing, dental implantation, spinal fusion or rapid repair of an ordinary injury. Future evidence must establish meaningful clinical outcomes, safety, patient selection and an authorised product pathway.

How does abaloparatide work?

Intermittent PTH1 receptor signalling

PTH1R is present on cells involved in bone remodelling. Brief, repeated receptor activation by an authorised abaloparatide regimen favours osteoblast activity and new bone formation. Bone turnover as a whole also changes; the desired result is a net increase in bone strength rather than simply a change in one laboratory marker.

Relationship to PTH-related protein

Abaloparatide was designed as an analogue of the active 1-34 region of PTHrP. It is often described as favouring a receptor conformation associated with a shorter signalling response than teriparatide. This is a mechanistic distinction, not proof that one medicine is universally safer or better for every patient.

Why treatment after the course matters

Bone mineral gained during anabolic therapy may decline after treatment stops. Clinical plans therefore commonly consider subsequent antiresorptive therapy. The choice and timing depend on the individual, prior therapy, kidney function, fracture risk and locally authorised guidance.

What has evidence found?

ACTIVE trial in postmenopausal women

The pivotal 18-month randomised ACTIVE trial enrolled 2,463 postmenopausal women with osteoporosis. Abaloparatide reduced new morphometric vertebral fractures compared with placebo and increased bone mineral density at the lumbar spine, total hip and femoral neck. The study also included an open-label teriparatide reference arm, but it was not designed to establish broad clinical superiority over teriparatide.

The European assessment summarises new spinal fractures in 0.5% of abaloparatide-treated participants and 4.2% of placebo-treated participants after 18 months. Relative reductions can sound dramatic; absolute event rates, trial eligibility and follow-up duration are essential context.

ACTIVExtend follow-on treatment

Participants who continued from ACTIVE into ACTIVExtend received alendronate. Results supported maintenance of bone-density gains and continued fracture-risk benefit after transition to an antiresorptive medicine. The evidence supports planned sequencing; it does not mean every patient should receive the same next medicine.

ATOM trial in men

The randomised ATOM study evaluated men with osteoporosis and showed significant bone-mineral-density increases at the lumbar spine, total hip and femoral neck compared with placebo over 12 months. These data supported expansion of the United States indication to men at high fracture risk. The European indication remains limited to postmenopausal women.

Evidence and regulatory position in 2026

Current regulatory and South African status

Abaloparatide is an authorised medicine in major jurisdictions, but its authorised population and treatment duration differ. TYMLOS has United States approval for qualifying postmenopausal women and men with osteoporosis at high fracture risk. ELADYNOS received European Union marketing authorisation on 12 December 2022 for postmenopausal women at increased fracture risk.

The September 2026 review found no publicly identifiable abaloparatide professional-information entry in SAHPRA’s online PI/PIL repository. That does not prove that no application, older registration, section 21 authorisation or other lawful access route exists. It means this page should not claim routine South African registration or availability without verification from SAHPRA and a lawful medicine supplier.

United States labelling says use for more than two years during a patient’s lifetime is not recommended except when fracture risk remains high. The European product information sets a maximum treatment duration of 18 months. This difference is a practical reminder that instructions cannot be transferred from one brand or jurisdiction to another.

Foreign approval does not itself authorise South African importation, compounding, promotion, dispensing or sale. Any South African pathway must be checked for the exact finished product, indication, prescriber, importer and supply arrangement.

How abaloparatide compares with other osteoporosis medicines

Known risks, contraindications and uncertainties

Common adverse effects include dizziness, nausea, headache, palpitations, faster heart rate, tiredness, upper abdominal discomfort and injection-site reactions. Hypercalciuria can occur, and urinary calcium may matter in people with active or previous kidney stones.

Orthostatic hypotension can occur, often within hours of administration. Initial use under circumstances where the person can sit or lie down is described in authorised information.

Abaloparatide can raise calcium. It is not recommended in pre-existing hypercalcaemia or an underlying hypercalcaemic disorder such as primary hyperparathyroidism.

Avoid use in people at increased baseline risk of osteosarcoma, including certain bone malignancies or metastases, prior skeletal radiation, Paget disease or unexplained alkaline-phosphatase elevation, according to the applicable label.

Severe kidney impairment is a contraindication under European product information; US information calls for careful use because exposure can rise. Local product information controls.

Pregnancy, breastfeeding and use in people with open epiphyses are outside the intended osteoporosis populations.

A transient rise in heart rate does not establish major cardiovascular harm, but cardiovascular risk and symptomatic tachycardia require clinical assessment.

Treatment and measurement safeguards

This page deliberately does not convert micrograms to syringe units, describe reconstitution or provide a regimen for bulk material. Authorised abaloparatide is supplied at a defined concentration in a validated multidose pen. Recreating a dose from powder introduces identity, concentration, sterility, stability and measurement risks that the clinical evidence did not test.

Clinical assessment may include fracture history, bone-density testing, calcium, vitamin D, kidney function and investigation for secondary causes of osteoporosis. Adequate calcium and vitamin D intake may be advised where dietary intake is insufficient, but supplementation must account for hypercalcaemia and stone risk.

Symptoms alone cannot show that bone is becoming stronger. Follow-up needs an agreed clinical plan, and treatment should not continue indefinitely simply because a pen or powder remains available.

Common questions

Is abaloparatide the same as teriparatide?

No. Both stimulate PTH1 receptors and build bone, but abaloparatide is a synthetic PTHrP analogue while teriparatide is recombinant human PTH(1-34). Their sequences, brands, evidence, devices and labels differ.

Is abaloparatide experimental?

No for its authorised osteoporosis indications in the United States and European Union. Other proposed uses remain investigational.

Is it approved for men?

The current United States label includes men with osteoporosis at high fracture risk or failure/intolerance of other therapy. The European authorisation is for postmenopausal women.

Why do duration limits differ?

Regulators authorise specific products using their own evidence assessment and wording. The US label and EU product information are not interchangeable.

Can it be used after teriparatide?

Treatment sequence is an individual specialist decision. Similar mechanism, prior anabolic exposure and lifetime-duration considerations must be reviewed.

Is it registered in South Africa?

No public abaloparatide entry was identified in SAHPRA’s online PI/PIL repository during this review. Registration and lawful availability must be confirmed directly for the exact product.

Does a supplier certificate prove equivalence to TYMLOS or ELADYNOS?

No. It does not establish the complete authorised formulation, sterility assurance, stability, pen performance, cold chain or regulatory approval.

Join for research and regulatory updates

Join the future research bulletin for important trial results, label changes, safety communications and South African registration or availability updates. Subscription does not provide medical advice, prescribing, product supply or injection instructions.

Consent wording for the future form: “I agree to receive evidence and regulatory updates by email. This service does not provide medical advice, personal dosing instructions or product supply.”

Sources and further reading

US Food and Drug Administration. TYMLOS (abaloparatide) prescribing information, application 208743, revision 2026.

European Medicines Agency. ELADYNOS (abaloparatide) EPAR and product information; EU marketing authorisation issued 12 December 2022.

Miller PD, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: the ACTIVE randomized clinical trial. JAMA. 2016;316:722-733.

Bone HG, et al. ACTIVExtend: abaloparatide followed by alendronate in postmenopausal women with osteoporosis. Journal of Clinical Endocrinology & Metabolism. 2018.

Czerwinski E, et al. Efficacy and safety of abaloparatide in men with osteoporosis: the ATOM randomized clinical trial. Journal of Bone and Mineral Research. 2022. ClinicalTrials.gov NCT03512262.

SAHPRA. Repository of Professional Information and Patient Information Leaflets, searched for abaloparatide, TYMLOS and ELADYNOS on 7 September 2026.

Editorial method: current regulator documents and pivotal peer-reviewed randomised evidence were prioritised over commercial pages. South African status is reported cautiously because absence from a public repository is not conclusive proof of non-registration. Review after major safety or registration changes, and no later than March 2027.